Laurion Capital Management LP Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Laurion Capital Management LP acquired a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 59,459 shares of the company’s stock, valued at approximately $1,890,000.

Several other large investors have also recently made changes to their positions in the business. Yale University purchased a new position in shares of RAPT Therapeutics in the 2nd quarter valued at $512,000. Adams Street Partners LLC acquired a new stake in RAPT Therapeutics during the 2nd quarter worth $256,000. Geode Capital Management LLC boosted its stake in RAPT Therapeutics by 34.3% during the 2nd quarter. Geode Capital Management LLC now owns 227,588 shares of the company’s stock worth $7,235,000 after purchasing an additional 58,075 shares during the period. Vanguard Group Inc. boosted its stake in RAPT Therapeutics by 21.6% during the 2nd quarter. Vanguard Group Inc. now owns 913,916 shares of the company’s stock worth $29,054,000 after purchasing an additional 162,516 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in RAPT Therapeutics during the 2nd quarter worth $291,000. 87.57% of the stock is currently owned by institutional investors.

Shares of RAPT stock traded up $0.71 during mid-day trading on Thursday, hitting $31.04. The stock had a trading volume of 420 shares, compared to its average volume of 444,024. RAPT Therapeutics, Inc. has a fifty-two week low of $14.63 and a fifty-two week high of $43.26. The firm has a market cap of $915.31 million, a PE ratio of -12.59 and a beta of 0.04. The company’s 50-day simple moving average is $33.30 and its 200-day simple moving average is $28.24.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Wednesday, August 11th. The company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.05. RAPT Therapeutics had a negative net margin of 1,219.06% and a negative return on equity of 45.84%. The firm had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $1.43 million. Research analysts expect that RAPT Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

In other RAPT Therapeutics news, insider Dirk G. Brockstedt sold 2,647 shares of the firm’s stock in a transaction dated Wednesday, August 11th. The shares were sold at an average price of $31.19, for a total transaction of $82,559.93. Following the completion of the transaction, the insider now directly owns 22,459 shares in the company, valued at approximately $700,496.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Ho sold 1,000 shares of the firm’s stock in a transaction dated Monday, August 2nd. The shares were sold at an average price of $30.52, for a total transaction of $30,520.00. The disclosure for this sale can be found here. Insiders sold 166,003 shares of company stock valued at $5,626,109 in the last quarter. Company insiders own 26.34% of the company’s stock.

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $56.00 price target on shares of RAPT Therapeutics in a research note on Monday, August 30th. Zacks Investment Research upgraded shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 11th. SVB Leerink reiterated a “buy” rating on shares of RAPT Therapeutics in a research note on Monday, October 4th. Finally, Piper Sandler initiated coverage on shares of RAPT Therapeutics in a research note on Sunday, June 20th. They issued an “overweight” rating and a $61.00 target price for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $59.86.

RAPT Therapeutics Profile

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Recommended Story: How to start trading in the forex market?

Want to see what other hedge funds are holding RAPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RAPT Therapeutics, Inc. (NASDAQ:RAPT).

Institutional Ownership by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.